Previous Close | 81.26 |
Open | 82.17 |
Bid | 80.89 x 50000 |
Ask | 81.15 x 50000 |
Day's Range | 79.71 - 81.81 |
52 Week Range | 57.26 - 88.38 |
Volume | |
Avg. Volume | 43 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Jul 24, 2024 - Jul 29, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Edwards Lifesciences stock underperformed its peers on Friday, sliding on light sales of its transcatheter aortic heart-valve replacements.
Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.